-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1685 Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

Program: Oral and Poster Abstracts
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Wenyu Shi1*, Yi Miao, MD2,3*, Jianyong Li, MD3,4, Jing Zhang, MD3,5*, Xuzhang Lu3,6*, Bingzong Li, MD, PhD3,7, Chunling Wang, PhD8,9,10*, Yun Zhuang3,11*, Yuqing Miao12*, Haiwen Ni, MD, PhD3,13*, Xiaoyan Xie3,14*, Jingyan Xu, MD3,15*, Yunping Zhang3,16*, Min Zhao3,17*, Min Xu, PhD9,18*, Wanchuan Zhuang, MD3,19*, Weiying Gu, PhD3,20*, Guoqiang Lin9,21*, Haiying Hua, MD3,22*, Jianfeng Zhu3,23*, Maozhong Xu3,24*, Tao Jia3,25*, Ping Liu, MD, PhD26* and Lijia Zhai3,27*

1Department of Oncology/Hematology, Affiliated Hospital of Nantong University, Jiangsu Cooperative Lymphoma Group (JCLG) and Jiangsu Histiocytosis Association Lymphoma Group (JHA-LG), Nantong, Jiangsu, China
2Lymphoma Center, Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3Jiangsu Cooperative Lymphoma Group (JCLG) and Jiangsu Histiocytosis Association Lymphoma Group (JHA-LG), Nanjing, China
4First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
5Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Tianjin, AL, China
6Department of Hematology, Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, China
7Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
8Department of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai'an, China
9Jiangsu Cooperative Lymphoma Group (JCLG)., Nanjing, China
10Department of Hematology, Huai'an First People's Hospital, Huai'an, China
11Department of Hematology, Wu Xi People's Hospital, Wuxi, China
12Department of Hematology, The First People’s Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China
13The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, China
14Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China
15Department of Hematology, The Affliated Drum Tower Hospital, Nanjing, China
16The Affiliated Yixing Hospital of Jiangsu University, Yixing, China
17Department of Hematology, Wuhu Second People's Hospital, Wuhu, China
18Zhangjiagang First Affiliated Hospital of Soochow University, Zhangjiagang, China
19The Second People's Hospital of Lianyungang, Lianyungang, China
20Department of Hematology, Changzhou First People's Hospital, Third Affiliated to Soochow University, Changzhou, China
21Department of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, China., Huai'an, China, China
22Affiliated Hospital of Jiangnan University, Jiangsu, CHN
23Department of Hematology, the People's Hospital of Taizhou, Taizhou, China
24The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, China
25The First People's Hospital of Lianyungang, Lianyungang, China
26The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Wuxi, CHN
27Department of Hematology, Affiliated Hospital of Yangzhou University, Yangzhou, China

Introduction:

Lymphoma is the most common underlying cause of secondary hemophagocytic lymphohistiocytosis (HLH). In Asian countries, T or NK-cell lymphoma-associated HLH (T/NK-LAHLH) is more common than B-cell lymphoma-associated HLH. There are no established prognostic markers for T/NK-LAHLH. Endothelial Activation and Stress Index (EASIX) is a marker of endothelial activation and could predict mortality in patients treated with allogeneic stem cell transplantation. Whether EASIX could predict survival in T/NK-LAHLH remains to be determined.

Materials and Methods:

Patients with T/NK-LAHLH were included. EASIX was calculated by the formula: lactate dehydrogenase (U/L)×creatinine (mg/dL)/thrombocytes (10⁹ cells per L). The diagnosis of HLH was based on the HLH-2004 criteria. Only patients with a histological diagnosis and follow-up were included. The subtyping was based on the 2016 World Health Organization classification of lymphoid neoplasms. X-tile was used to determine the best cutoff of EASIX for survival prediction.

Results:

A total of 212 cases of T/NK-LAHLH were identified. The most common subtype of T/NK cell malignancy was extranodal NK/T cell lymphoma, nasal type (57, 26.9%) followed by aggressive NK cell leukemia (55, 25.9%) and peripheral T cell lymphoma, not otherwise specified (29, 13.7%). The best cutoff of EASIX for predicting 60-day survival was 40.1. Patients with high EASIX values (>40.1) had a significantly poorer 60-day survival than those with low EASIX values (≤40.1) (60-day survival rate: 15.6% vs. 63.9%, p<0.0001). Patients with high EASIX also showed significantly poorer overall survival (median survival: 14 days vs. 79 days, p<0.0001). For patients with NK cell malignancies, a higher EASIX also significantly predicted a reduced 60-day survival rate (p<0.0001) and overall survival (p<0.0001). Patients with high EASIX values showed significantly lower levels of hemoglobin, neutrophil count, albumin, and fibrinogen and higher levels of aspartate aminotransferase, alanine aminotransferase, and triacylglycerol (p values all < 0.05). EASIX>40.1 (hazards ratio[HR] 3.60, 95%CI: 2.31-5.60; p<0.0001), fibrinogen≤1.5g/L (HR 1.67, 95%CI: 1.07-2.58; p=0.023), and age>60 (HR 1.76, 95%CI:1.14-2.71; p=0.011) were identified as independent predictors of worse 60-day survival in multivariate analysis. A prognostic index was established by combining these three independent predictors. We assigned a weighted score of 1 to fibrinogen and age, and 2 to EASIX. Finally, a prognostic index for T/NK-LAHLH (T/NK-LAHLH-PI) ranged from 0 to 5 was established (T/NK-LAHLH-PI: low-risk 1, intermediate-risk 2, high-risk ≥2). T/NK-LAHLH-PI significantly predicted different 60-day survival rates (low-risk 77.3% vs. intermediate-risk 50.1% vs. high-risk 24.9%, p<0.0001) and overall survival (median survival: low-risk 340 days vs. intermediate-risk 63 days vs. high-risk 20 days, p<0.0001).

Conclusions:

Our study demonstrated that EASIX was a robust marker for predicting outcomes in patients with T/NK-LAHLH. T/NK-LAHLH-PI, a prognostic index containing EASIX, could be used to predict the outcomes of patients with T/NK-LAHLH.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH